Eccogene Enters into a Collaboration Agreement with AstraZeneca to Develop and Commercialize ECC5004 for Cardiometabolic Diseases
Shots:
- Under the terms of the agreement, Eccogene has granted AstraZeneca the exclusive rights to develop & commercialize Eccogene's ECC5004 worldwide, except for China, where the two companies will co-develop & co-commercialize ECC5004 for Cardiometabolic Diseases incl. obesity & type-2 diabetes
- Eccogene will receive an up front payment of $185M & is eligible for up to $1.825B as clinical, regulatory & commercial based milestone payments, plus tiered royalties
- ECC5004 is a small molecule GLP-1RA that is currently being evaluated for safety & efficacy in a P-I clinical trial in patients with type 2 diabetes & healthy participants across the US
Ref: PR Newswire | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
